placebo pregnenolone
Dietary SupplementSugar pill, taken twice a day
NCT Number: NCT00615511
Four-month trial of pregnenolone or placebo, as an additional medication, to treat negative symptoms and cognitive decline in schizophrenia. After four months the scores on the negative symptom scale should be lower and the scores on the cognitive tests should be higher than they were at study entry, compared with people who do not take any additional medication.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
University of Medicine & Dentistry of New Jersey- University Behavioral HealthCare, Piscataway, New Jersey, United States
Pregnenolone is a steroid health supplement which is readily available in health food stores. We are using it in this study at higher doses than you would normally take as a health supplement because preliminary studies have indicated that negative symptoms improve and certain aspects of cognition improve at these doses. We do not require you to stop your existing treatment in order to enter the study. After four months we will test your symptoms and cognition and ask if you would like to continue taking pregnenolone, at no cost, in a follow-up study designed to determine the long-term costs and benefits of taking pregnenolone.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sugar pill, taken twice a day
500mg in tablet form taken orally twice a day
Time frame: every month for 4 months
Time frame: every two months for four months
Weill Medical College of Cornell University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01945333
Mental Disorders, Psychotic Disorders
Brooklyn, New York, United States
View Trial DetailsNCT00001486
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial DetailsNCT00942981
Mental Disorders, Psychotic Disorders
Bethesda, Maryland, United States
View Trial DetailsNCT06007105
Acute and Transient Psychotic Disorder, Bipolar Type I Disorder With Psychotic Symptoms
Blantyre, Southern Region, Malawi
View Trial Details